Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure
Following the wind down of its R&D arm, Theravance will generate revenue from two partnered, commercialised assets.
FDA releases hold on second of Intellia’s ATTR-CM gene therapy trials
Faron and City of Hope to develop Phase II trial of bexmarilimab for r/r MDS
Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint
FDA tells uniQure to conduct another study of Huntington’s gene therapy
BlueWind’s Revi urinary incontinence device demonstrates three-year efficacy
Analysis
View More
Themes
View MoreCinnaGen Enters EU Market with EMA Approval for Zandoriah®
CinnaGen today announced that the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Zandoriah® (teriparatide),…
More themes
Data Insights
View MoreLeading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View more
Digital Magazine
View MorePharma Technology Focus Magazine
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Oncology trial systems debut at SCOPE 2026 as AI adoption accelerates
Biorce secures $52.5m in Series A to expand AI clinical trial tech
Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs
Patient-centric approaches thrive on wearables and remote access in trials